Large gap with delayed quotes
Analysis date: 03.03.2026
Global Evaluation
Neutral
Neutral
The stock is classified in the neutral zone since 21.11.2025.
Interest
Strong
Strong
Three stars since 13.02.2026.
Earnings Rev Trend
Negative
Negative
Compared to seven weeks ago, the analysts have lowered their earnings per share estimates. This negative trend began 10.10.2025 at a price of 94.71.
Evaluation
Neutral
Neutral
Based on its growth potential and our own criteria, we believe the share price is currently fairly priced.
MT Tech Trend
Positive
Positive
The dividend-adjusted forty day technical trend is positive since 10.02.2026.
4wk Rel Perf
15.14%
15.14%
The four-week dividend-adjusted overperformance versus SP500 is 15.14%.
Sensibility
Middle
Middle
The stock has been on the moderate-sensitivity level since 21.11.2025.
Bear Market Factor
Middle
Middle
On average, the stock is likely to decline with the index.
Bad News Factor
Low
Low
When the stock's pressure is specific, the market sanction on average is 2.59%.
Mkt Cap in $bn
19.47
19.47
With a market capitalization >$8bn, ZIMMER BIOMET is considered a large-cap stock.
G/PE Ratio
0.81
0.81
A ratio (Forecasted Growth + Estimated Dividend Yield/ Estimated Price Earnings) below 0.9 indicates that investors must pay a premium for the estimated growth potential:
LT P/E
11.02
11.02
The estimated PE is for the year 2027.
LT Growth
7.90%
7.90%
The annualized growth estimate is for the current year to 2027.
Avg. Nb analysts
27
27
Over the last seven weeks, an average of 27 analysts provided earnings per share estimates.
Dividend Yield
1.03%
1.03%
The twelve month estimated dividend yield represents 11.33% of earnings forecasts.
Beta
52
52
For 1% of index variation, the stock varies on average by 0.52%.
Correlation
0.32
0.32
Stock movements are strongly independent of index variations.
Value at Risk
18.99
18.99
The value at risk is estimated at USD 18.99. The risk is therefore 19.39%. This value is based on the historical volatility for a medium time period (1 month) with a confidence of 95%.
First Analysis Date
24.07.2002
24.07.2002